Biotech Startups

Ponda is a biomaterials company developing textiles from regenerative fibres, specifically processing cattails grown in regenerative wetlands, as an alternative to fabrics sourced from ancient and endangered forests. The company serves apparel brands, designers, and retailers seeking sustainable textile solutions that protect global ecosystems.

3 investors

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

3 investors

Portable Diagnostic Systems (PDS) builds point-of-care diagnostic devices that combine microfluidics, lab-on-a-chip technology, biosensing, and AI to deliver lab-quality testing outside traditional labs. Its products target settings such as secondary care facilities, pharmacies, retail clinics, ambulances, and the home for early disease detection and health monitoring.

3 investors

Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.

3 investors

Possible Ventures is a venture capital firm that invests in mission-driven teams building companies with frontier technology. Its portfolio spans areas such as biotech, materials, fusion energy, and space exploration.

3 investors

Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]

3 investors

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.

3 investors

Precision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.

3 investors

Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.

3 investors

Prilenia is a biotechnology company developing treatments for neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS). Its research centers on pridopidine, a compound that activates the sigma-1 receptor to restore brain pathways affected by neurodegeneration.

3 investors

Priothera is a clinical-stage biotech developing mocravimod (an S1P receptor modulator) for hematologic malignancies such as acute myeloid leukemia. The company focuses on drug development for cancer patients undergoing hematopoietic stem cell transplantation.

3 investors

Procyrion develops medical devices for circulatory support in heart failure treatment, supported by a team of cardiologists and medical device industry veterans.

3 investors

Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. The company's TULSA-PRO therapeutic system enables precise ablation of diseased prostate tissue in a commercial-stage medical technology setting.

3 investors

PrognomiQ is a clinical-stage company developing blood-based tests for early detection and treatment of cancer and other complex diseases using multi-omics data. It combines proprietary large-scale proteomic data with genomic, metabolomic, and other health data on its own platform to build diagnostic test products.

3 investors

ProQR develops medicines for patients with unmet medical needs, focusing on therapeutic development in biotech.

3 investors

Protein Distillery makes Prewtein, a yeast-based clean-label protein ingredient with high protein content and functional properties like gelation, solubility, and emulsification. The non-GMO, non-novel ingredient is used to reduce additives and replace animal-based ingredients such as eggs in food products.

3 investors

ProteinQure is a clinical-stage biotech company that designs novel peptides for therapeutic delivery using its proprietary ProteinStudio computational platform powered by AI and molecular simulations. The company focuses on peptide-drug conjugates for tissue-specific and cell-specific delivery of therapeutics, with applications in oncology, renal disease, and blood-brain barrier transport.

3 investors

ProteoWise develops the Hyperblot benchtop instrument for high-throughput multiplexed proteomics, letting researchers load samples and antibody panels to obtain quantified western-style protein data. It targets life-science researchers working in areas such as neuroscience, cancer, and immunology.

3 investors

Qnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.

3 investors

QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria. The company operates R&D laboratories in San Diego, California, working alongside Shionogi's research labs in Japan.

3 investors

QualisureDx develops diagnostic tests using machine-learning and molecular analysis to identify unique cancer properties and guide personalized treatment decisions for oncologists. The company serves cancer care teams seeking to match patients with appropriate therapies that maximize efficacy while minimizing toxicity.

3 investors

Quantum-Si develops next-generation protein sequencing technology that enables single amino acid detection by combining biology, chemistry, artificial intelligence, and semiconductor technology. The platform makes protein analysis accessible to research labs for drug discovery, diagnostics, and scientific research in the post-genomic era.

3 investors

Qubit Pharmaceuticals develops novel drug candidates using quantum physics, AI, and computational chemistry through its ATLAS platform for high-precision molecular simulation, modeling, and molecule generation. Its pipeline focuses on oncology, inflammation, and antiviral/pandemic-response programs, with fully owned and partnered drug discovery projects.

3 investors

QV Bioelectronics develops GRACE, an implantable electric field delivery platform designed to treat aggressive cancers by delivering continuous therapeutic electric fields directly to tumor sites. The company targets oncology indications including glioblastoma, brain metastases, and pancreatic cancer.

3 investors